Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30242843 | 1.00 | KMT2A (0.60) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL5384122 | 0.88 | KMT2A (0.56) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL1686806 | 0.87 | EPHX2 (0.56) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL31309889 | 0.87 | KMT2A (0.50) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL10661146 | 0.87 | KMT2A (0.50) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL29400248 | 0.87 | KMT2A (0.50) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL31603929 | 0.85 | KMT2A (0.56) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL13137482 | 0.85 | KMT2A (0.51) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL30905361 | 0.85 | KMT2A (0.56) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL15692103 | 0.85 | KMT2A (0.56) | KMT2AEPHX2FABP7FABP5MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137502-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20100311946-A1 | Solid Phase Peptide for the Production of Goserelin | MALLINCKRODT INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010141276-A1 | SOLID PHASE PEPTIDE SYNTHESIS PROCESS FOR THE PRODUCTION OF GOSERELIN | MALLINCKRODT INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141276-A1 | SOLID PHASE PEPTIDE SYNTHESIS PROCESS FOR THE PRODUCTION OF GOSERELIN | MALLINCKRODT INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| EP-0518655-B1 | Solid phase peptide synthesis | ZENECA LTD (GB) | 1997-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311946-A1 | Solid Phase Peptide for the Production of Goserelin | GCG, GNRHR, GIPR | KMT2A 790/4885EPHX2 4154/4885FABP7 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.